1. ScholarBank@NUS

Wee Joo Chng

rp04705

Collaboration Map View Statistics Email Alert RSS Feed

Profile

Full Name
Wee Joo Chng
Variants
Chng W.J
Chng, W.J.
Chng W.-J.
Wee Joo Chng
Chng, W.-J.
 
Main Affiliation
 
Faculty
 
Email
mdccwj@nus.edu.sg
 
Other emails
 

Publications

Refined By:
Department:  CANCER SCIENCE INSTITUTE OF SINGAPORE

Results 1-20 of 157 (Search time: 0.014 seconds).

Issue DateTitleAuthor(s)
11-Aug-20223-Chloro-3-methyl-2,6-diarylpiperidin-4-ones as Anti-Cancer Agents: Synthesis, Biological Evaluation, Molecular Docking, and In Silico ADMET PredictionRamalingam, Arulraj ; Mustafa, Nurulhuda ; Chng, Wee Joo ; Medimagh, Mouna; Sambandam, Sivakumar; Issaoui, Noureddine
220-Jun-2022A genomic-augmented multivariate prognostic model for the survival of Natural-killer/T-cell lymphoma patients from an international cohort.Lim, Jing Quan ; Huang, Dachuan ; Chan, Jason Yongsheng; Laurensia, Yurike; Wong, Esther Kam Yin; Cheah, Daryl Ming Zhe; Chia, Burton Kuan Hui; Chuang, Wen-Yu; Kuo, Ming-Chung; Su, Yi-Jiun; Cai, Qing-Qing; Feng, Yanfen; Rao, Huilan; Feng, Li-Na; Wei, Pan-Pan; Chen, Jie-Rong; Han, Bo-Wei; Lin, Guo-Wang; Cai, Jun; Fang, Yu; Tan, Jing; Hong, Huangming; Liu, Yanhui; Zhang, Fen; Li, Wenyu; Poon, Michelle LM; Ng, Siok-Bian ; Jeyasekharan, Anand ; Ha, Jeslin Chian Hung; Khoo, Lay Poh; Chin, Suk Teng; Pang, Wan Lu; Kee, Rebecca; Cheng, Chee Leong ; Grigoropoulos, Nicholas Francis; Tang, Tiffany; Tao, Miriam; Farid, Mohamad ; Puan, Kia Joo; Xiong, Jie; Zhao, Wei-Li; Khor, Chiea Chuen ; Hwang, William; Kim, Won Seog; Campo, Elias; Tan, Patrick ; Teh, Bin Tean ; Chng, Wee-Joo ; Rötzschke, Olaf; Tousseyn, Thomas; Huang, Hui-Qiang; Rozen, Steve; Lim, Soon Thye ; Shih, Lee-Yung; Bei, Jin-Xin; Ong, Choon Kiat 
33-Sep-2021A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)Chen, Yunxin ; Gopalakrishnan, Sathish Kumar; Ooi, Melissa ; Sultana, Rehena ; Lim, Li Hui; Grigoropoulos, Nicholas ; Ong, Shin Yeu ; Xu, Mingge; Chng, Wee Joo ; Goh, Yeow Tee ; Nagarajan, Chandramouli
415-Apr-2023A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological MalignanciesChee, Cheng E ; Ooi, Melissa ; Lee, Soo-Chin ; Sundar, Raghav ; Heong, Valerie; Yong, Wei-Peng ; Ng, Chin Hin ; Wong, Andrea; Lim, Joline SJ ; Tan, David SP ; Soo, Ross ; Tan, Joshua TC; Yang, Song; Thura, Min; Al-Aidaroos, Abdul Qader; Chng, Wee Joo ; Zeng, Qi ; Goh, Boon-Cher 
51-Dec-2023A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myelomaChng, WJ ; Lonial, S; Morgan, GJ; Iida, S; Moreau, P; Kumar, SK; Twumasi-Ankrah, P; Villarreal, M; Dash, AB; Vorog, A; Zhang, X; Suryanarayan, K; Labotka, R; Dimopoulos, MA; Rajkumar, SV
61-Jun-2021A unique rhinologic manifestation of multiple myelomaSeah, Jun Jie; Chng, Wee Joo ; Thong, Mark Kim Thye
720-Sep-2018Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosisTeoh, Phaik Ju ; An, Omer ; Chung, Tae-Hoon ; Chooi, Jing Yuan ; Toh, Sabrina HM ; Fan, Shuangyi ; Wang, Wilson ; Koh, Bryan TH; Fullwood, Melissa J ; Ooi, Melissa G ; de Mel, Sanjay; Soekojo, Cinnie Y; Chen, Leilei ; Ng, Siok Bian ; Yang, Henry ; Chng, Wee Joo 
82015Aberrant nuclear factor-kappa B activity in acute myeloid Leukemia: From molecular pathogenesis to therapeutic targetZhou J. ; Ching Y.Q. ; Chng W.-J. 
91-Mar-2011Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profilingNg, Siok-Bian ; Selvarajan, Viknesvaran; Huang, Gaofeng; Zhou, Jianbiao ; Feldman, Andrew L; Law, Mark; Kwong, Yok-Lam; Shimizu, Norio; Kagami, Yoshitoyo; Aozasa, Katsuyuki; Salto-Tellez, Manuel; Chng, Wee-Joo 
1028-Apr-2014Allogeneic haematopoietic SCT for natural killer/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study GroupTse, E.; Chan, T.S.Y.; Koh, L.-P.; Chng, W.-J. ; Kim, W.-S.; Tang, T.; Lim, S.-T.; Lie, A.K.W.; Kwong, Y.-L.
1123-Feb-2021Application of Advanced Mass Spectrometry-Based Proteomics to Study Hypoxia Driven Cancer ProgressionVinaiphat, Arada; Low, Jee Keem; Yeoh, Kheng Wei ; Chng, Wee Joo ; Sze, Siu Kwan
1227-Jan-2020Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphomade Mel, S.; Rashid, M.B.M.; Zhang, X.Y.; Goh, J.; Lee, C.T.; Poon, L.M.; Chan, E.H.L. ; Liu, X.; Chng, W.J. ; Chee, Y.L.; Lee, J.; Yuen, Y.C.; Lim, J.Q. ; Chia, B.K.H.; Laurensia, Y.; Huang, D.C.; Pang, W.L.; Cheah, D.M.Z.; Wong, E.K.Y.; Ong, C.K. ; Tang, T. ; Lim, S.T. ; Ng, S.B. ; Tan, S.Y. ; Loi, H.-Y. ; Tan, L.K. ; Chow, E.K. ; Jeyasekharan, A.D. 
131-Sep-2020ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia.Zhou, Jianbiao ; Yiying Quah, Jessie ; Ng, Yvonne ; Chooi, Jing-Yuan ; Hui-Min Toh, Sabrina ; Lin, Baohong; Zea Tan, Tuan ; Hosoi, Hiroki ; Osato, Motomi ; Seet, Qihui; Ooi, Lisa AG; Lindmark, Bertil; McHale, Mark; Chng, Wee-Joo 
1428-Mar-2013ATM-dependent spontaneous regression of early Eμ-myc-induced murine B-cell leukemia depends on natural killer and T cells.Croxford, J.L. ; Tang, M.L.; Pan, M.F. ; Huang, C.W.; Kamran, N.; Phua, C.M.; Chng, W.J. ; Ng, S.B. ; Raulet, D.H.; Gasser, S. 
15Jul-2017Belinostat exerts antitumor cytotoxicity through the ubiquitin-proteasome pathway in lung squamous cell carcinomaKong, L.R ; Tan, T.Z ; Ong, W.R; Bi, C; Huynh, H ; Lee, S.C ; Chng, W.J ; Eichhorn, P.J.A ; Goh, B.C 
161-Mar-2022Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple MyelomaZhou, Jianbiao ; Chng, Wee-Joo 
171-Jan-2016Bortezomib-related neuropathy may mask CNS relapse in multiple myeloma: A call for diligenceAbid, Muhammad Bilal; De Mel, Sanjay; Abid, Muhammad Abbas; Tan, Kong Bing; Chng, Wee Joo 
1829-Apr-2021CAR T-cell therapy in multiple myeloma: more room for improvementTeoh, Phaik Ju ; Chng, Wee Joo 
1917-Mar-2017Carfilzomib and Dexamethasone vs Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma: Results of the Phase 3 Study ENDEAVOR (NCT01568866) According to Age SubgroupHeinz Ludwig; Meletios A. Dimopoulos; Philippe Moreau; Wee Joo Chng ; Hartmut Goldschmidt; Roman Hajek; Thierry Facon; Ludek Pour; Ruben Niesvizky; Albert Oriol; Laura Rosinol; Aleksandr Suvorov; Gianluca Gaidano; Tomas Pika; Katja Weisel; Vesselina Goranova-Marinova; Antonio Palumbo; Heidi Gillenwater; Nehal Mohamed; Sanjay Aggarwal; Shibao Feng; Douglas Joshua
201-Jun-2017Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVORChng, W-J ; Goldschmidt, H; Dimopoulos, MA; Moreau, P; Joshua, D; Palumbo, A; Facon, T; Ludwig, H; Pour, L; Niesvizky, R; Oriol, A; Rosinol, L; Suvorov, A; Gaidano, G; Pika, T; Weisel, K; Goranova-Marinova, V; Gillenwater, HH; Mohamed, N; Feng, S; Aggarwal, S; Hajek, R